- Home
- SAN vs SNY Comparison
SAN vs SNY Comparison
Compare SAN & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAN
- SNY
- Stock Information
- Founded
- SAN 1857
- SNY 1994
- Country
- SAN Spain
- SNY France
- Employees
- SAN N/A
- SNY N/A
- Industry
- SAN Commercial Banks
- SNY Biotechnology: Pharmaceutical Preparations
- Sector
- SAN Finance
- SNY Health Care
- Exchange
- SAN Nasdaq
- SNY Nasdaq
- Market Cap
- SAN 125.3B
- SNY 113.4B
- IPO Year
- SAN 1987
- SNY N/A
- Fundamental
- Price
- SAN $10.06
- SNY $46.97
- Analyst Decision
- SAN Strong Buy
- SNY Buy
- Analyst Count
- SAN 1
- SNY 4
- Target Price
- SAN N/A
- SNY $61.50
- AVG Volume (30 Days)
- SAN 4.2M
- SNY 2.7M
- Earning Date
- SAN 10-28-2025
- SNY 10-24-2025
- Dividend Yield
- SAN 1.67%
- SNY 3.40%
- EPS Growth
- SAN 17.29
- SNY 118.56
- EPS
- SAN 0.97
- SNY 8.65
- Revenue
- SAN $58,905,460,953.00
- SNY $53,714,621,258.00
- Revenue This Year
- SAN $22.88
- SNY $1.53
- Revenue Next Year
- SAN N/A
- SNY $7.06
- P/E Ratio
- SAN $10.33
- SNY $5.43
- Revenue Growth
- SAN 5.45
- SNY 15.65
- 52 Week Low
- SAN $4.43
- SNY $44.73
- 52 Week High
- SAN $10.16
- SNY $60.12
- Technical
- Relative Strength Index (RSI)
- SAN 65.21
- SNY 43.02
- Support Level
- SAN $9.96
- SNY $46.50
- Resistance Level
- SAN $10.16
- SNY $47.69
- Average True Range (ATR)
- SAN 0.12
- SNY 0.68
- MACD
- SAN 0.01
- SNY -0.18
- Stochastic Oscillator
- SAN 87.65
- SNY 36.14
About SAN Banco Santander S.A. Sponsored ADR (Spain)
Santander's focus is on retail and commercial banking. Latin America is geographically the most significant operation, with Brazil making the largest contribution. Its continental European business is mainly in Spain and Portugal. Santander's UK presence is the result of its acquisition of Abbey building society. In the US, Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.